- Home
- UTL vs IMTX Comparison
UTL vs IMTX Comparison
Compare UTL & IMTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UTL
- IMTX
- Stock Information
- Founded
- UTL 1984
- IMTX N/A
- Country
- UTL United States
- IMTX Germany
- Employees
- UTL N/A
- IMTX N/A
- Industry
- UTL Power Generation
- IMTX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- UTL Utilities
- IMTX Health Care
- Exchange
- UTL Nasdaq
- IMTX Nasdaq
- Market Cap
- UTL 811.5M
- IMTX 865.5M
- IPO Year
- UTL N/A
- IMTX N/A
- Fundamental
- Price
- UTL $47.31
- IMTX $9.39
- Analyst Decision
- UTL Hold
- IMTX Strong Buy
- Analyst Count
- UTL 1
- IMTX 5
- Target Price
- UTL $55.00
- IMTX $15.00
- AVG Volume (30 Days)
- UTL 128.7K
- IMTX 815.8K
- Earning Date
- UTL 11-03-2025
- IMTX 11-17-2025
- Dividend Yield
- UTL 3.79%
- IMTX N/A
- EPS Growth
- UTL N/A
- IMTX N/A
- EPS
- UTL 2.91
- IMTX N/A
- Revenue
- UTL $493,800,000.00
- IMTX $152,823,253.00
- Revenue This Year
- UTL $7.06
- IMTX N/A
- Revenue Next Year
- UTL $7.63
- IMTX N/A
- P/E Ratio
- UTL $16.35
- IMTX N/A
- Revenue Growth
- UTL N/A
- IMTX 83.61
- 52 Week Low
- UTL $44.61
- IMTX $3.30
- 52 Week High
- UTL $61.51
- IMTX $11.40
- Technical
- Relative Strength Index (RSI)
- UTL 54.06
- IMTX 78.64
- Support Level
- UTL $46.40
- IMTX $6.90
- Resistance Level
- UTL $48.17
- IMTX $9.54
- Average True Range (ATR)
- UTL 0.90
- IMTX 0.47
- MACD
- UTL 0.26
- IMTX 0.25
- Stochastic Oscillator
- UTL 79.87
- IMTX 95.21
About UTL UNITIL Corporation
Unitil Corp is a holding company, through its subsidiaries it is engaged in the local distribution of electricity and natural gas throughout its service territories in the states of New Hampshire, Massachusetts, and Maine. The Company has two operating and reportable segments: Utility Electric Operations and Utility Gas Operations. Majority of revenue is gained from Electric Segment.
About IMTX Immatics N.V.
Immatics NV is a biotechnology company engaged in the research and development of T-cell redirecting immunotherapies for the treatment of cancer patients. The company earns revenue through strategic collaboration agreements with third-party pharmaceutical and biotechnology companies. The company derives its maximum revenue from United States.